Evidence map›Paper›PMID 28197521›Full record

ArticleJournal of nephropharmacology2017

Impact of

Marzieh Kafeshani, Mahmoud Mirhosseini, Ali Momeni, Rahmatollah Rabiei, Mahmoud Rafieian-Kopaei

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of nephropharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Heliyon · 2024
    Article
  2. Journal of nephropharmacology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Marzieh KafeshaniNutrition and Food Science School, Isfahan University of Medical of Sciences, Isfahan, Iran.
Mahmoud MirhosseiniMedical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Ali MomeniMedical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Rahmatollah RabieiMedical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Mahmoud Rafieian-KopaeiMedical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Shahrekord University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PATIENTS AND

methodsThis study performed on 61 hyperlipidemia patients. They assigned in control and intervention groups. The control group received 40 mg/day of lovastatin and intervention group received 40 mg/day of Lovastatin plus 2 g/day powder of

Indexed as

CholesterolHumanHyperlipidemiaKelussia odoratissimaTriglyceride

Identifiers

PMID28197521
PMCPMC5295657
OpenAlexW2544685736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.